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Abstract
We examine the suitability of three methods using patient-level data to eval-
uate the time-varying impacts of national healthcare guidelines. Such guide-
lines often codify progressive change and are implemented gradually; for ex-
ample, National Institute for Health and Care Excellence (NICE) suspected-
cancer referral guidelines. These were revised on 23/06/2015, to include more
cancer symptoms and test results (“features”), partly reflecting changing
practice. We explore the time-varying impact of guideline revision on time to
colorectal cancer diagnosis, which is linked to improved outcomes in decision-
analytic models. We included 11,842 patients diagnosed in 01/01/2006–
31/12/2017 in the Clinical Practice Research Datalink with England can-
cer registry data linkage. Patients were classified by whether their first
pre-diagnostic cancer feature was in the original guidelines (NICE-2005) or
was added during the revision (NICE-2015-only). Outcome was diagnos-
tic interval: time from first cancer feature to diagnosis. All analyses ad-
justed for age and sex. Two difference-in-differences analyses used either a
Pre (01/08/2012–31/12/2014, n=2,243) and Post (01/08/2015–31/12/2017,
n=1,017) design, or event-study cohorts (2006–2017 vs 2015) to estimate
change in diagnostic interval attributable to official implementation of the
revised guidelines. A semiparametric varying-coefficient model analysed the
difference in diagnostic interval between the NICE groups over time. Af-
ter model estimation, primary and broader treatment effects of guideline
content and implementation were measured. The event-study difference-in-
differences and the semiparametric varying-coefficient methods showed that
shorter diagnostic intervals were attributable to official implementation of the
revised guidelines. This impact was only detectable by pre-to-post difference-
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in-differences when the pre/post periods were selected according to the esti-
mation results from the varying-coefficient model. Formal tests of the para-
metric models, which are special cases of the semiparametric model, suggest
that they are misspecified. We conclude that the semiparametric method is
well suited to explore the time-varying impacts of guidelines codifying pro-
gressive change.
Research highlights
• Different methods can be used to measure the time-varying and treat-
ment effects of guidelines
• We compare difference-in-differences and semiparametric varying-coefficient
methods
• The 2015 UK national suspected-cancer referral guidelines are used as
an example
• Two of the three methods identify time-varying effects











Many countries have bodies that develop national healthcare guidelines; for
example, The National Institute for Health and Care Excellence (NICE) in
England, The American College of Physicians in the USA, and the National
Health and Medical Research Council in Australia. A guideline’s impact is
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likely to vary over time, dependent on structural and behavioural change,
and may even start before publication if the guideline codifies improving
clinical practice. As randomised controlled trials are often impracticable or
unethical, there is considerable interest in methods applicable to observa-
tional data for quantifying the time-varying impacts of health-policy change
(Craig et al., 2012). The current paper explores methods for capturing the
time-varying effects of guidelines on health outcomes within repeated cross-
sectional data with a control group. We illustrate these methods using the
NICE suspected-cancer referral guidelines, first introduced in 2005 (NICE,
2005) and revised in 2015 (NICE, 2015). The guidelines aim to expedite can-
cer diagnosis for symptomatic patients attending primary care, because late
diagnosis is associated with poor survival (Elliss-Brookes et al., 2012). The
2005 guidelines were based mainly on secondary care evidence, and included
signs, symptoms and abnormal test results (collectively termed “clinical fea-
tures”) suggesting a risk of undiagnosed cancer ≥5% (NICE, 2005). The 2015
revision was based solely on primary-care evidence and added new clinical
features. It also lowered the threshold risk to 3%, to liberalise investigation
enough to expedite cancer diagnosis without overwhelming clinical services
or increasing patient harms from over-investigation (NICE, 2015). The NICE
guidelines apply in England, but are also endorsed in Wales and Northern
Ireland, and are supported by The Independent Cancer Taskforce (Kumar,
2015).
One notable feature of these guidelines is that they codify the evidence base
and best practice that develops over time, a characteristic not commonly en-
countered in intervention-evaluation studies. The most conservative measure
of the effect of the guidelines is to measure the impact from the date of their
official implementation, and this is the primary impact we measure. Broader
effects can also be measured, such as those linked to guideline content and
occurring before official implementation. This requires identifying a key mo-
ment in time from which we can explore change, which can be challenging.
We explore three methods that use a control group to assess the impact of
revising the suspected-cancer guidelines on time to diagnosis of colorectal
cancer – an outcome linked with improved survival in decision-analytic mod-
els (Tørring et al., 2013). The three methods are pre-to-post and event-study
difference-in-differences, and a semiparametric varying-coefficient model.
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The pre-to-post difference-in-differences method is widely applied in health-
services research (Streeter et al., 2017), and was used to quantify the impact
of the original 2005 NICE suspected-cancer referral guidelines on the time-
liness of cancer diagnosis (Neal et al., 2014). The outcome measure was
diagnostic interval, i.e. the time between first presentation of a cancer symp-
tom to primary care and diagnosis (Weller et al., 2012). Diagnostic intervals
were shorter in 2007–08 compared with 2001–02; however, this was only at-
tributable to the new guidelines in two cancer sites (oesophagus and cervix)
(Neal et al., 2014). It is possible that the guidelines had little impact, and/or
that Neal et al.’s chosen control group did not capture the secular trend well.
Alternatively, the pre-to-post difference-in-differences method may not be
well equipped to measure time-varying changes in impact. This possibility is
one focus of our paper.
The event-study difference-in-differences has been used to explore the phased
impact of policy, by introducing a series of dummy variables into the difference-
in-differences regression model, each indicating time relative to a new pol-
icy (Wing et al., 2018). These dummies are typically yearly or monthly,
as used to examine the effects of US government school-desegregation poli-
cies on racial mix over time (Reber, 2005), and health-insurance mandates
on mammography and breast cancer diagnosis (Bitler & Carpenter, 2016).
This method can also be used to explore the time trends associated with
pre-intervention anticipatory effects; for example, to examine the impact of
changes in medical care insurance (Alpert, 2016; Brot-Goldberg et al., 2017)
and hospital reform (Kolstad & Kowalski, 2012).
Finally, we consider the semiparametric varying-coefficient model (Li et al.,
2002). Here, the pattern of time-varying effects is not restricted by any pre-
specified parametric functional form, such as occurs with the common prac-
tice of adding interaction terms to a regression model. To our knowledge, the
semiparametric varying-coefficient model is rarely applied in healthcare re-
search. It has been used to explore time trends in the control and intervention
arms within randomised controlled trials (Gilbert et al., 2019; Wasan et al.,
2017), and the time-varying aspects of tumour characteristics on disease-free
survival in breast cancer in an observational dataset (Natarajan et al., 2009).
There are three main ways in which the semiparametric model, applied to
repeated cross-sectional data, provides additional insights over parametric
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models in healthcare studies assessing the impact of interventions, partic-
ularly when the intervention is a guideline as we consider here. First, the
method can account for the time-varying impact of all control variables (for
example, age, sex, and intervention). Second, applying the semiparametric
varying-coefficient model, it is possible to test the validity of the conven-
tional parametric specifications, such as the pre-to-post and the event-study
difference-in-differences methods. Third, once the varying-coefficient model
has been run, treatment effects of guideline implementation, as well as the
combining effects of both guideline content and subsequent implementation
can be estimated. Given the novelty of the method, our aim is to illustrate
the method’s potential and any assumptions required without being prescrip-
tive about which of these features are ultimately used by researchers.
Our study adds to the existing literature in the following five ways. First,
we describe the three methods and summarise their distinguishing charac-
teristics. Second, we show how the semiparametric model can be used in
preliminary analysis for data visualisation of the time-varying aspects of co-
variates. Third, we show that the pre-to-post and event-study difference-in-
differences models are special cases of the semiparametric varying-coefficient
model, enabling a formal test of the parametric models against the varying-
coefficient model. Fourth, we show how the semiparametric method can be
used in causal analysis to measure treatment effects. Finally, we report the
first comparison of these difference-in-differences methods and the semipara-
metric varying-coefficient model to assess the impact of national guidelines
in patient-level health records, using NICE referral guidelines for suspected
colorectal cancer as an illustration.
2. Data
2.1. Study setting and inclusion criteria
The setting was primary care and the data sources were the Clinical Practice
Research Datalink (CPRD), a dataset of observational, anonymised, patient
records in UK primary care, with partial linkage to National Cancer Registra-
tion and Analysis Service (NCRAS) and Office for National Statistics (ONS)
data (Herrett et al., 2015). Ethics approval by the Independent Scientific
Advisory Committee (protocol 16 037) was obtained on 30/10/2017. The
CPRD reduced temporarily in size from 2013 to 2017, so we anticipate fewer
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Table 1: Features of colorectal cancer, by version of NICE suspected-cancer referral guide-
lines
In NICE 2005 Added in NICE 2015
Rectal bleeding Abdominal pain
Iron-deficiency anaemia Faecal occult blood
Change in bowel habit Weight loss
Rectal mass
Abdominal mass
patients in the latter part of the study period, which was 1 January 2005
to 31 December 2017 inclusive. Patient inclusion criteria were: adults aged
≥18 years with an incident colorectal cancer diagnosis between 1 January
2006 and 31 December 2017, who were registered with the general practice
for at least 1 year before their diagnosis. Patients were excluded if they:
were diagnosed via screening; were registered with general practices in Scot-
land (where NICE suspected-cancer referral guidelines are not applicable);
had multiple index cancers; had not attended their general practice in the
year before diagnosis; or had not presented with any clinical features listed




We identified CPRD codes for features of undiagnosed colorectal cancer (i.e.
abnormal test results and symptoms listed in NICE guidelines (Table 1))
in the year before diagnosis (NICE, 2005, 2015). Cancer diagnosis date was
taken as the first diagnostic CPRD code, and is reliable (Boggon et al., 2013).
Diagnosis date was validated by linked NCRAS data, where available, with
the NCRAS data taking precedence if discrepant.
The outcome variable was diagnostic interval: the time between the first
feature of cancer and diagnosis (Weller et al., 2012). Diagnostic interval was
constrained to 1 year before diagnosis following standard practice, and was
log-transformed as it has a right-skewed distribution (Hamilton et al., 2009).
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2.2.2. Dummy variable for the NICE guidelines
For all three analysis methods, a dummy “NICE2015” variable was created by
classifying all patients by their first recorded feature of cancer. The variable
was set to 1 for patients with index feature(s) only listed in NICE-2015
guidelines and not previously in the 2005 guidelines, and 0 otherwise. In
essence, the NICE-2015 group identifies patients captured by the expanded
guidelines (Table 1).
2.2.3. Other control variables
The CPRD provided variables for sex, year of birth and region (England,
Wales, Northern Ireland or Scotland). Age at diagnosis was estimated by
assigning the birth date as 1 July of the year provided by the CPRD, and
was entered into all analyses as a continuous variable. Patient-level Townsend
Deprivation Index data (for England only), calculated using unadjusted 2001
census data, were provided by ONS.
In the main analysis, we control for patient sex and age at diagnosis. We
have also conducted a series of sensitivity analyses by controlling for patient
region (England versus Wales or Northern Ireland) and deprivation index.
3. Methods
3.1. Pre-to-post difference-in-differences
In the pre-to-post difference-in-differences method (Eq.(1)), the outcome of
interest (diagnostic interval) is measured in four groups, control (NICE-2005)
and treated (NICE-2015-only), before and after the treated group is managed
according to the new guidelines. The effect attributable solely to official
implementation of the new guidelines is estimated by the coefficient for the
interaction term (δ3) between the dummy variables dT (indicating before or
after revised guideline implementation) and NICE2015 (indicating control or
treated group) (Card & Krueger, 1994):
y = δ0 + δ1NICE2015 + δ2dT + δ3dT ·NICE2015 +Wβ + u, (1)
where vector y represents the outcomes of all observations, W is a matrix for
other explanatory variables (for example, age and sex), and u is the standard
residual error term with zero conditional mean.
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In this study, we apply pre-to-post difference-in-differences to estimate the
impact of implementing the revised NICE guidelines on log-transformed
diagnostic interval. It is worth noting that the pre-to-post difference-in-
differences model specified by Eq.(1) can only identify, under the so-called
parallel assumption (see Appendix A for details), the average treatment
effect of the new guideline’s implementation. It can neither accommodate
the time-varying feature of this effect, nor capture the impact of the new
guideline’s content before its official implementation.
We use data from patients diagnosed before (1 August 2012 – 31 Decem-
ber 2014) or after (1 August 2015 – 31 December 2017) revised guideline
publication on 23 June 2015. Having comparable time periods before and
after the guideline implementation date avoids seasonality effects. The anal-
yses accounted for the correlation among individuals within the same general
practices (clusters) and adjusted for age at diagnosis and sex. We checked for
differences in the age and sex distributions between the Pre and Post peri-
ods. We use robust standard errors to account for heteroscedasticity and the
models are run with log(age) and with age-squared to check for non-linearity.
In sensitivity analyses, we adjusted for deprivation and region (see Appendix
C for detailed results).
3.2. The event-study difference-in-differences method
The event-study difference-in-differences (Eq.(2)) method estimates the time-
varying effects of the revised guidelines:






λtdtNICE2015 +Wβ + e (2)
where dt is a dummy variable representing the time period (which is annual
here but can be any predetermined frequency) relative to the new guide-
line implementation, where t = −Tl,−Tl + 1, ..., 0, 1, ..., Tu. The period of
guideline implementation is represented by t=0, with negative t values be-
fore implementation and positive t values after. −Tl represents the earliest
time period in the data, and Tu the most recent. NICE2015 is defined as in
Eq.(1), i.e. a dummy variable for treatment. For t > 0, λt measures the av-
erage treatment effect of the new guideline’s implementation in time period
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t after the implementation. For t < 0, λt can reflect the trend of the antici-
patory effect of the new guideline’s content before official implementation. e
is the standard residual error term with zero conditional mean.
In this study we apply event-study difference-in-differences to estimate the
time-varying impact of NICE guideline revision on log-transformed diagnostic
interval. We use data from patients diagnosed with cancer between 1 Jan-
uary 2006 and 31 December 2017. We classified patients by the year of
their index feature of cancer, using multiple dummy variables between 2005
(Tl = 10) and 2017 (Tu = 2) (see Eq.(2) above). Interaction terms between
NICE category and each year dummy were sought, omitting year 2015 as
the reference category. By applying this event-study difference-in-differences
method, we identity under a variant parallel assumption (see Appendix A for
details), the time-varying treatment effect of the guideline’s implementation
on a yearly basis. It also visualises the pre-implementation anticipatory effect
of the new guideline’s content (which are also yearly varying). For technical
details, please see Appendix A. The analyses account for the correlation
among individuals within the same general practices (clusters) and adjusts
for age at diagnosis and sex. We check for differences in the age and sex
distributions between the annual cohorts. In sensitivity analyses, we adjust
for deprivation and region (see Appendix C).
3.3. The semiparametric varying-coefficient method
The semiparametric varying-coefficient method is represented by Eq.(3):
y = δ0(ct) + δ1(ct)NICE2015 +Wβ(ct) + ε, (3)
where NICE2015 and W are defined as in Eq. (1) and Eq. (2), and ε is
the standard residual error term with zero conditional mean. In the varying-
coefficient model (Eq.(3)), NICE2015 and W are called regressors, and ct is
referred to as a covariate. ct represents time relative to the new guideline’s im-
plementation on 23 June 2015, with positive values for post-implementation
time periods, negative values for pre-implementation time periods, and zero
for time periods coinciding with guideline implementation. In particular,
ct = −TL,−TL + 1, ..., 0, 1, ..., TU , where −TL and TU represent the earliest
and latest time points, respectively (equivalent to −Tl and Tu in Eq.(2)).
Note that, depending on the data frequency, ct can be a discrete (month or
year) or a continuous (day) variable. In this study, we take the unit of ct
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as a day, so we have TL=3825 (1 January 2005) and TU=922 (31 December
2017). In this model, we assume E(u |NICE2015,W, ct ) = 0. The model can
account for fixed effects associated with individual general practices (Feng
et al., 2017; Rodriguez-Poo & Soberon, 2014), but this was not implemented
here, owing to high level estimation demand and complexity.
We apply the semiparametric varying-coefficient method to estimate the im-
pact of NICE guideline revision on the difference in mean log-transformed
diagnostic interval between NICE-2015-only and NICE-2005 groups, for pa-
tients diagnosed with cancer between 1 January 2006 and 31 December 2017.
Analyses were carried out using the ‘np’ package in R (Hayfield and Racine,
2008).
We illustrate three potentials ways in which the semiparametric varying-
coefficient method can be applied to obtain additional insights over the
difference-in-differences parametric models.
First, we capture the time-varying (on a daily basis) difference in the diagnos-
tic interval between the two groups (NICE-2005 and NICE-2105-only) over
the entire time frame of the data. This allows visualisation of time-varying
trends that may be associated with the new guidelines. The granularity of
data analysis on a daily basis matches the typical reporting frequency of pri-
mary and secondary care patient records. Though the event-study difference-
in-differences method also accounts for the time-varying impact of the new
guidelines, the reporting frequency adopted is on a yearly basis, because con-
sidering shorter periods, such as per month or per day, would be cumbersome
to implement using dummy variables and over-consume degrees of freedom
(Wing et al., 2018). An additional feature of the semiparametric method is
that it permits separate reporting of the time-varying coefficients of each re-
gressor (for example, age, sex, and intervention). The corresponding results
are presented in Section 4.3.1.
Second, we illustrate how the semiparametric varying-coefficient model can
be used to test the functional forms imposed by the other two methods,
i.e. the pre-to-post and the event-study difference-in-differences methods, to
fit the data. In Section 3.4, we introduce the formal tests of the varying-
coefficient model versus each of the two conventional difference-in-differences
methods, respectively.
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Finally, we illustrate how, once the semiparametric varying-coefficient model
is run, the estimated coefficients can be used to measure the average treat-
ment effect of guideline implementation itself on a particular day after the
official implementation (i.e. ct > 0). This is measured by the difference be-
tween the coefficient of NICE2015 for the date of ct > 0 and the coefficient
for the date of guideline implementation (i.e. δ1(ct) – δ1(0)). In addition,
without re-running the model, we can measure broader treatment effects.
In this example, it is interesting to explore the impact of the guideline’s
content, which we assume begins at time ct0 . The impact is measured as
δ1(ct) – δ1(ct0), where ct > ct0 . This is challenging because there is great
uncertainty around the actual date of ct0 . To demonstrate the advantage of
this method, we chose to measure the impact of the guideline’s content from
30 June 2014, the date of a political announcement encouraging the recogni-
tion of early signs of cancer. Arguably, this announcement is weakly linked
to the revised guideline’s content. We can use this date to illustrate how the
method captures the impact of the guideline’s content, by subtracting the
coefficient for NICE2015 on the date of the announcement (ct0 = −357) from
the coefficient for NICE2015 on any date after the political announcement
(ct > −357), i.e. δ1(ct) – δ1(−357). It should be noted that after guideline
implementation (i.e. for ct > 0), this measure captures the treatment effect
of both the guideline’s content and its implementation. The technical details
on model estimation and average treatment effect identification are presented
in Appendix B.
3.4. Model Comparison
In Eq.(3), the coefficients δ0(ct), δ1(ct), and β(ct) are all dependent on ct.
In contrast to the parametric model specifications in Eq.(1) and Eq.(2), the
coefficients are not specified as a certain functional form; rather, unknown
functional forms are assumed and estimated. In this sense, the paramet-
ric model specifications of Eq.(1) and Eq.(2) are two special cases of the
semiparametric model, Eq.(3). In particular, Eq.(1) can be written as:




δ0 if ct < 0





δ1 if ct < 0
δ1 + δ3 if ct ≥ 0
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·NICE2015 +Wβ + u. (5)
In the same sense, it is a special case of Eq.(3), i.e.
δ0(ct) =
{
δ0 if ct is in the time period of guideline implementation year




δ1 if ct is in the time period of guideline implementation year
δ1 + λt if ct is in the time period of dt = 1
,
and β(ct) ≡ β.
This specification test can be used in isolation of any future features of the
semiparametric model. In particular we note that that in this form the δ1(ct)
from the semiparametric varying-coefficient model is contaminated by any
pre-existing difference between treated and control groups (as indicated by
δ1 in Eq.(1) and Eq.(2)). While the estimand δ1(ct) is looking at differences
between trends in the control (NICE-2005) and treated (NICE-2015-only)
groups, rather than identifying a particular treatment effect, it is a useful
first step in visualising the time-varying trends.
This comparison is drawn to show that the pre-to-post and event-study
difference-in-differences model specifications are special cases of the semi-
parametric varying-coefficient model. This enables a formal test of the semi-
parametric varying-coefficient model versus the parametric models, using an
approach proposed by Li and Racine (2010). The model specification test is
outlined in more detail in Appendix B.3.
Importantly, this model specification test is distinct from any of the modifi-
cations needed to enable causal estimation using the semiparametric method,




The CPRD provided 25,011 patients with an incident colorectal cancer di-
agnosis between 1 January 2006 and 31 December 2017. Of these, 13,169
were excluded, mostly because they did not present with features of colorec-
tal cancer (n=9,693) or because they resided in Scotland (n=3,105) where
different guidelines apply. Patients diagnosed following screening (n=52), or
with multiple index cancers (n=52), or who did not attend general practice
(n=4) were also excluded, leaving 11,842 patients (n=6,477 men, 54.7%) in
the analyses. Table 2 summarises the demographic characteristics of the pa-
tients included in the three different methods of analysis.
For the pre-to-post difference-in-differences analysis, there were fewer pa-
tients in the Post (n=1,017) than in the Pre (n=2,243) group. For the
event-study difference-in-differences and semiparametric varying-coefficient
models, the numbers of patients in the annual cohorts declined from 2013 to
2017 (Table 2). These falls are consistent with the known reducing size of
the CPRD.
The percentages of NICE-2015-only and NICE-2005 patients was the same
in the Pre and Post groups, and varied slightly year on year between 2005
and 2017 but no overall trend was apparent (Table 3).
There were no discernible differences in age distribution between the Pre and
Post groups (see Figure 1), or between the annual cohorts (Table 2).
The sex distribution indicated a marginally greater proportion of men in the
Post compared to the Pre group, and in years 2016–17 compared with 2005–
15 (Table 2).
The assumption of parallel trends in the difference-in-differences models was
explored by visual inspection of the data (see Figure C.1 in supplementary
Appendix C). The general direction of change of mean diagnostic interval
was broadly similar in the NICE-2015-only and NICE-2005 groups, apart
from during the year of guideline revision (2015).
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Table 2: Demographic characteristics of the patients included in pre-to-post and event-
study difference-in-differences analyses, and in semiparametric varying-coefficient analysis
(SPVC)
Analysis type Perioda N (%) Ageb % male
Pre-post diff-in-diff Prec 2,243 (68.8) 70.2 (13.1) 53.7
Postd 1,017 (31.2) 68.8 (13.3) 58.4
Total 3,260 (100) 69.8 (13.2) 55.2
Event-study
diff-in-diff
& SPVC 2005 299 (2.5) 70.3 (13.5) 53.5
2006 1,239 (10.5) 70.1 (12.0) 53.0
2007 1,213 (10.2) 70.5 (11.9) 53.8
2008 1,174 (9.9) 70.7 (11.9) 54.4
2009 1,191 (10.1) 70.3 (12.7) 54.2
2010 1,213 (10.2) 70.7 (12.1) 57.4
2011 1,148 (9.7) 69.5 (13.0) 53.8
2012 1,131 (9.6) 70.0 (12.9) 55.3
2013 964 (8.1) 70.3 (13.3) 54.9
2014 837 (7.1) 70.4 (12.9) 51.3
2015 653 (5.5) 70.3 (13.4) 54.1
2016 486 (4.1) 68.6 (12.9) 61.3
2017 294 (2.5) 68.2 (13.2) 59.2
Total 11,842 (100) 70.1 (12.6) 54.7
Notes:
a Period in which feature of possible cancer presented.
b Age (in years) at diagnosis, mean (SD).
c Pre: 1 Aug 2012 to 31 Dec 2014.
d Post: 1 Aug 2015 to 31 Dec 2017.
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Table 3: Numbers of patients by NICE group and study period in the pre-to-post and
event-study difference-in-differences and in the semiparametric varying-coefficient models
Analysis type Cohort NICE-2005 NICE-2015-only Total
Pre-post diff-in-diff Prea 1,331 (59.3) 912 (40.7) 2,243
Postb 603 (59.3) 414 (40.7) 1,017
Total 1,934 1,326 3,260
Event-study diff-in-diff
& SPVC 2005 154 (51.5) 145 (48.5) 299
2006 684 (55.2) 555 (44.8) 1,239
2007 717 (59.1) 496 (40.9) 1,213
2008 677 (57.7) 497 (42.3) 1,174
2009 955 (55.0) 536 (45.0) 1,191
2010 678 (55.9) 535 (44.1) 1,213
2011 650 (56.6) 498 (43.4) 1,148
2012 691 (61.1) 440 (38.9) 1,131
2013 560 (58.1) 404 (41.9) 964
2014 500 (59.7) 337 (40.3) 837
2015 401 (61.4) 252 (38.6) 653
2016 281 (57.8) 205 (42.2) 486
2017 177 (60.2) 117 (39.8) 294
Total 6,825 (57.6) 5,017 (42.4) 11,842
Notes:
a Pre: 1 Aug 2012 to 31 Dec 2014.
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Figure 1: Distribution of age at diagnosis for patients in the main pre-to-post difference-
in-differences analysis. Teal bars: Pre (n=2,243); black outlined bars: Post (n=1,017)
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Table 4: Pre-to-post difference-in-differences regression analysis results
Coefficient 95% CI p
δ0 3.789 3.569 to 4.009 <0.0001
δ1 0.059 –0.046 to 0.164 0.271
δ2 0.089 –0.009 to 0.187 0.075
δ3 –0.139 –0.324 to 0.046 0.141
Age at diagnosis 0.001 –0.002 to 0.004 0.485
Sex (female vs male) 0.104 0.024 to 0.185 0.011
Notes:
See Eq.(1) for model specification:
δ0 is mean log-transformed diagnostic interval for men at age 0 in the NICE-2005 group
in the Pre cohort.
δ1 is the difference in mean log-transformed diagnostic interval in the Pre cohort between
the NICE-2015-only and NICE-2005 groups.
δ2 is the Pre to Post difference in mean log-transformed diagnostic interval in the NICE-
2005 group.
δ3 is the Pre-to-Post change in mean log-transformed diagnostic interval attributable to
NICE 2015.
Age at diagnosis was entered as a continuous variable.
4.2. Results from difference-in-differences methods
The pre-to-post difference-in-differences analysis results, adjusting for age
and sex, are reported in Table 4. No secular trend in diagnostic inter-
val (δ2: 0.089, 95% confidence interval –0.009 to 0.187, p=0.075), or im-
pact of guideline revision (δ3: –0.139, –0.324 to 0.046, p=0.141) was found.
Women have 10% longer diagnostic intervals than men (0.104, 0.024 to 0.185,
p=0.011).
The event-study difference-in-differences analysis results are plotted in Fig-
ure 2 (see Table C.1 in supplementary Appendix C for model estimates).
The trend of the anticipatory effect is to reduce diagnostic intervals prior
to 2015. In 2017, there was moderate evidence that the impact of official
guideline implementation in 2015 was to reduce diagnostic intervals by 30%
(–0.307, 95% CI –0.616 to 0.003, p=0.053) (Figure 2).
Supplementary Appendix C reports sensitivity analyses, showing no non-
linear effects of age (Table C.2), no heterogeneous effects of age between
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Figure 2: Data analysed using event-study difference-in-differences. Red vertical line
denotes the year that NICE suspected-cancer guidelines were revised. Red horizontal
line denotes no difference in diagnostic interval between NICE-2015-only and NICE-2005
groups. See Table C.2 in supplementary Appendix C for values
4.3. Results from varying-coefficient model
4.3.1. Data visualisation of time-varying effects
Figure 3 shows the percentage change in mean diagnostic interval (with 5%
and 95% percentiles) between the NICE-2015-only and NICE-2005 groups
over time estimated by the semiparametric varying-coefficient method. The
percentage change oscillated with a period of approximately 1 year, and an
amplitude of between 10 and 20 percentage points.
Between 1 July 2005 and 1 July 2008, NICE-2015-only patients had diagnos-
tic intervals that were between 20% and 40% longer than those of NICE-2005
patients. From 1 July 2008 until shortly before the revised guidelines were
introduced, the difference in diagnostic interval between the two groups re-
duced to zero. After the revised guidelines were introduced, NICE-2015-only
patients had diagnostic intervals that were 20% to 30% shorter than those
for NICE-2005 patients.
There are no suggestions of disparities in the data in terms of percentage
change over time in mean diagnostic interval between men and women (Fig-
















































Date of index feature
Figure 3: Mean diagnostic interval (DI) in NICE-2015-only patients versus NICE-2005
patients between 2006 and 2017. Data analysed using semiparametric varying-coefficient
method. Black dashed vertical line denotes the introduction of revised suspected-cancer
referral guidelines on 23 June 2015. Black dashed horizontal line denotes no difference in





































95%CI % Change in DI (female vs male)
Figure 4: Trend in gender coefficient over time. Black dashed vertical line denotes the
introduction of revised suspected-cancer referral guidelines on 23 June 2015. Black dashed












































95% Confidence interval % Change in DI
Figure 5: Trend in age coefficient over time. Black dashed vertical line denotes the in-
troduction of revised suspected-cancer referral guidelines on 23 June 2015. Black dashed
horizontal line denotes no difference in diagnostic interval with age
Figure 6 reports the trend in the intercept (mean log diagnostic interval)
over time. With wide confidence intervals, there is no discernible change in
absolute diagnostic interval over the whole study period.
By conducting the model specification test (see Appendix B.3), we can re-
ject both the pre-to-post difference-in-differences model specification and the
event-study difference-in-differences model specification, at the 1% signifi-
cance level.
4.3.2. Treatment effect estimation
The primary, and most conservative, treatment effect to measure is that of
official guideline implementation. The average treatment effect of official
guideline implementation on a particular day after 23 June 2015 (i.e. ct > 0)
is estimated by the difference between the coefficients for NICE2015 on the
date of interest and on the date of guideline implementation (i.e. δ1(ct) –
δ1(0)).
We also illustrate how the broader effects of guidelines can be measured, by
selecting the date of 30 June 2014 (ct => −357), when the then Secretary of
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Figure 6: Trend in the intercept. Black dashed vertical line denotes the introduction of
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Figure 8: Treatment effect of guideline content and implementation, assuming guideline
content impact began on 30 June 2014 (solid vertical red line)
of the early signs of cancer. This type of treatment effect can be measured
by δ1(ct)− δ1(−375).
The treatment effect of official policy implementation is plotted in Figure
7. The results indicate a trend towards a positive treatment effect of the
guidelines to reduce diagnostic intervals, but the 90% confidence interval is
wide and the upper limit remains greater than zero, suggesting considerable
uncertainty. It is unfortunate that the CPRD was reducing in size over this
time, which may contribute to this uncertainty.
The broader treatment effects are plotted in Figure 8, which shows an imme-
diate impact of guideline content to reduce diagnostic interval, followed by
a rebound rise and then subsequent and sustained fall after official guideline
implementation on 23 June 2015.
4.4. Robustness checks on pre-to-post difference-in-differences analysis
In a series of robustness checks, we examined the effect of changing the Pre
and Post periods. The results are presented in supplementary Appendix C.
Changing the start time in four 10-day increments within the confines of
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the data availability did not alter the model estimates (Table C.7). Varying
the start time and the width (Pre: 1/7/2013–31/7/2013; Post: 1/7/2017–
31/7/2017) to examine immediate impacts had no effect. However, analyses
including 1-year Pre (2013) and Post (2017) windows sandwiching guideline
implementation in 2015 reported a significant reduction in diagnostic interval
associated with guideline implementation (δ3 –0.393, 95% confidence interval
−0.693 to −0.093, p=0.010) (Table C.8).
Next, we selected Pre (16/3/2014–31/12/2014) and Post (16/3/2017–31/12/2017)
periods informed by the results of the semiparametric varying-coefficient
analyses. The coefficient comparing diagnostic interval between NICE-2015-
only and NICE-2005 groups became significantly and consistently negative
on 16 March 2017. The results showed a significant impact of NICE guideline
revision on diagnostic interval (δ3 –0.476, 95% CI –0.807 to –0.146, p=0.005)
(Table C.8).
Finally, to enable comparison of all three models, we included all observations
in the original data set, and set the cut-off time as the date of guideline
revision (23 June 2015). This showed a significant impact of NICE guideline
revision (δ3 –0.215, 95%CI –0.374 to –0.055, p=0.008) (Table C.8).
4.5. Sensitivity analyses for unobserved confounding
In sensitivity analyses (see supplementary Appendix C), we examined the
effects of potential confounders other than age and sex. Region is a potential
confounder because of geographical variation in the recognition and report-
ing of cancer symptoms (Maja Niksic et al., 2016) and in the dissemination
of guidelines in England versus Wales or Northern Ireland. In sensitivity
analyses for all three models, a binary variable for region (England versus
Wales or Northern Ireland) was included as a regressor. The main results
were unaffected, but diagnostic intervals are shorter in England than in Wales
or Northern Ireland (pre-to-post difference-in-differences: –0.218, 95%CI –
0.306 to –0.129, p<0.0001, Table C.9; event-study: –0.309, –0.359 to –0.259,
p<0.0001, Table C.10). The semiparametric varying-coefficient model re-
ported a trend for this discrepancy to reduce over time (Figure C.3).
Deprivation may act as a confounder through effects on the recognition and
reporting of cancer symptoms and consulting behaviour (M. Niksic et al.,
2015). In sensitivity analyses, all three methods analysed England-only
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data (owing to Townsend data availability), including a binary explanatory
variable for deprivation (most deprived quintiles 4 and 5, versus least de-
prived quintiles 1–3). The coefficient for deprivation was not significant in
the pre-to-post difference-in-differences (Table C.11), but in the event-study
difference-in-differences (Table C.12) and semiparametric varying-coefficient
(Figure C.4) analyses, there was evidence that diagnostic interval tended to
be longer with increasing deprivation.
5. Discussion
This is the first study, to our knowledge, that compares methods to mea-
sure the time-varying impacts of national guidelines using repeated, cross-
sectional patient-level data.
Our data source was the CPRD – one of the largest database of anonymised
patient records in the world, and a widely used resource for primary care re-
search and epidemiology studies (Herrett et al., 2015). Robust methods were
used for case identification in the electronic medical record (Watson et al.,
2017). Our sample sizes, of several hundred patients per year, were adequate
for measuring the secular trend and divergences from it. Limitations relating
to the temporary reduction in CPRD size towards the end of the study are
discussed below.
The event-study difference-in-differences and the semiparametric varying-
coefficient methods showed that revising the suspected-cancer referral guide-
line was associated with shorter diagnostic intervals for colorectal cancer. In
contrast, these impacts were only detectable by the pre-to-post difference-
in-differences method when the start dates and widths of the pre and post
periods were carefully selected according to the varying-coefficient model
estimates (Section 4.4). Furthermore, the semiparametric tests of coeffi-
cient functional specification suggest that the pre-to-post and event-study
difference-in-differences models are misspecified.
This study builds on econometric literature (Li et al., 2002; Li and Racine,
2010) developed to explore time-varying effects. Given that the semipara-
metric method has not yet been widely applied in health services research,
our aim has been to illustrate the method’s potential without being pre-
scriptive on its use. The strengths of the semiparametric varying-coefficient
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method are now summarised briefly. The time-varying impacts are not re-
stricted by any specified parametric functional form, such as the common
practice of adding interaction terms to regression models. The semiparamet-
ric model is able to uncover more granular changes in time trends compared
with the difference-in-differences methods. The model can be used to explore
the time-varying effects of confounders such as age and sex, and is useful for
the visualisation of data generally. The method can also be used to test the
specification of difference-in-differences models, and can be adapted for use
in causal analysis.
Finally, we note that a potential challenge for all methods is how to capture
any behavioural changes arising before guideline implementation – owing to
the difficulty of identifying when these impacts begin. The conventional
difference-in-differences methods typically approach this problem by only
measuring the impact from the date of implementation. To estimate impact
before that requires re-running these models, assuming different reference
periods. In contrast, the semiparametric method needs to be run only once
– after which it is possible to identify key dates from which we can explore
the broader treatment effects of guidelines.
We conclude that the semiparametric varying-coefficient method offers use-
ful features that provide additional insights into the time-varying aspects of
repeated cross-sectional data.
5.1. Limitations
The reducing size of the CPRD in 2013–17 occurred as contributing general
practices moved away from the CPRD’s required IT system, Vision. The
similar demographics of the annual cohorts in the current study suggests
that any variation in the numbers of CPRD practices over time did not in-
troduce bias. We carried out more detailed examination for associated bias
in a separate study (Price et al., under review by Cancer Epidemiology), but
found none.
For causal analysis, all three models are based on different versions of the
parallel trends assumption as outlined in Appendix A and Appendix B.
Meeting the parallel trends assumption is essential for reliable estimates be-
cause it ensures that the only difference between the groups is exposure to the
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guidelines (Abadie, 2005). All the methods require careful selection of the
control group to ensure that it accurately represents secular trends, which
are then assumed to hold for the treated group. It could be argued that
the semiparametric method makes the strongest parallel trends assumption,
being on a daily basis. For this reason, we have not been prescriptive in how
researchers should apply the semiparametric varying-coefficient model, and
show that its other features are valuable in their own right.
The challenges of meeting the parallel trends assumption have led to liter-
ature looking at, among other things, synthetic controls (Kreif et al., 2016;
O’Neill et al., 2016) which weight the combination of groups used as controls
against which the treatment group is compared. Propensity score weight-
ing within difference-in-differences can be used to weight the composition of
treatment pre, treatment post, control pre, and control post groups to ensure
a balanced set of characteristics which largely overcomes the misspecification
due to observed covariates (Stuart et al., 2014).
5.2. Comparison with emerging literature
The methods that we have reviewed apply a variant of the regression difference-
in-differences design to take account of time-varying effects. Callaway and
Sant’Anna (2019) have recently proposed an alternative to the regression
difference-in-differences method that applies a generalised propensity score
method, using probit or logit, to sample a proportional effect for the treated
group. This method was developed to accommodate multiple treatment ef-
fects arising from interventions that: (1) start at different time points and
(2) can influence multiple time periods. A useful addition of their paper
is a proposed procedure to aggregate multiple treatment effects – which is
particularly helpful to measure the effect of complex staggered implemen-
tation. But this feature is not required here as the NICE suspected-cancer
guidelines were launched nationwide within a short space of time. In prin-
ciple, the Callaway and Sant’Anna (2019) method can be used to capture
the time-varying treatment effect, but, similar to the event-study difference-
in-differences method, the time periods are restricted to a relatively small
number and would be very difficult to implement with a high-frequency time
variable, such as daily data as in our application.
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5.3. Future research
In the current paper we have explored the abilities of different models
to capture the time-varying effects of new guidelines after their implementa-
tion. It is also important to measure the pre-implementation effects of new
guidelines that codify gradual improvements in clinical practice over time.
To do this requires identifying a key moment in time, for example the release
date of underpinning research findings, from which we can measure change.
While we have illustrated how the semiparametric method is able to do this
in principle, a full examination of this issue was beyond the scope of the
current paper, and will be the subject of further research.
In the current paper we are able to explore the impact of guidelines on diag-
nostic interval. To inform decision analytic models of early cancer diagnosis
there is also need to explore other outcomes, such as primary care interval
(i.e. time from first cancer feature to referral), referrals and stage at diag-
nosis. These outcomes are all essential parts of the evidence base needed to
link expedited cancer diagnosis to improved cancer outcomes. Such research
will require the CPRD dataset to be linked with Hospital Episode Statistics
data to follow the patient from primary to secondary care, which is beyond
the scope of this current study.
We have also shown how the semiparametric model can explore the impact
the trends in other variables, such as age and sex. One extension of this
feature would be to apply the semiparametric model to explore whether
the impact of the new guidelines is heterogeneous across age at diagnosis
and gender. This extension would enable researchers to explore the po-
tential for unintended consequences of the guidelines on the distribution of
health across observed confounders – which would be important had the
time-varying trends in age and sex alone depicted change.
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Appendix
This document includes three sections. In the first two sections, we discuss in
detail the treatment effect identification and measurement by different meth-
ods, i.e. the pre-to-post difference-in-differences (DID) method, the event-
study DID method and the semiparametric varying-coefficient method, the
estimation method for the varying-efficient model and the formal test for the
varying-coefficient model versus the parametric model specifications. The
description and discussion is under the particular context of our applica-
tion, i.e. to examine the impact of new national guidelines in 2015 on the
diagnostic interval for colorectal cancer using repeated cross-sectional data
from CPRD between 1 January 2006 and 31 December 2017. In the last sec-
tion (Appendix C), we present the extra results from a series of sensitivity
analyses and robustness checks.
Appendix A. Treatment Effect Identification from the Pre-to-post
DID Method and the Event-study DID Method
In this section, we discuss the treatment effect identification from the pre-to-
post DID method and the event-study DID method. First, we consider the
pre-to-post DID method, i.e.
y = δ0 + δ1NICE2015 + δ2dT + δ3dT ·NICE2015 +Wβ + u, (A.1)
where dT is a dummy variable indicating before (dT = 0) or after (dT = 1)
the new guideline implementation. By using this pre-to-post DID method,
we aim to identify the average treatment effect of the new guideline imple-
mentation for the treated sub-population (ATT).
Let y1(i, dT ) represent the potential diagnostic interval of individual i, when
the first recorded feature of cancer observed during time period of dT is one
of the NICE-2015-only features, and y0(i, dT ) indicates the potential diag-
nostic interval of individual i, when his/her first recorded feature of cancer
observed during time period of dT is one of the NICE-2005 features. The
ATT of the new guideline implementation conditional on W can be defined
as ATT = E[y1(i, 1)− y0(i, 1)|Wi, NICE2015,i = 1].
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To reduce notation, we drop the argument i, the indicator of individuals. To
identify the ATT, we have to rely on the so-called parallel assumption, as
stated below:
Assumption A.1. E[y0(1) − y0(0)|W,NICE2015 = 1] = E[y0(1) −
y0(0)|W,NICE2015 = 0].
Assumption A.1 states that the average difference in the diagnostic intervals
before and after the new guideline implementation for the control and treated
groups, conditional on the other observed factors W , would have been the
same in the absence of the new guideline implementation. Under Assumption
A.1, if the pre-to-post DID method of Eq(A.1) is applied, the ATT can be
identified and measured by δ3 in Eq (A.1), because
ATT = E[y1(1)− y0(1)|W,NICE2015 = 1]
= E[y1(1)− y0(0) + y0(0)− y0(1)|W,NICE2015 = 1]
= E[y1(1)− y0(0)|W,NICE2015 = 1]− E[y0(1)− y0(0)|W,NICE2015 = 1]
= E[y1(1)− y0(0)|W,NICE2015 = 1]− E[y0(1)− y0(0)|W,NICE2015 = 0]
=
[(
δ0 + δ1 + δ2 + δ3 +Wβ)−
(


















where dt is a dummy variable indicating the year relative to the new guideline
implementation year (i.e. 2015), with t > 0 for years after 2015, t = 0 for
2015, and t < 0 for a year before 2015. By applying the event-study DID
method, we are able to identify the average treatment effect, conditional on
the observed factors W , of the new guideline implementation in a certain
year for the treated sub-population (ATT (t|W )).
Let y1(i, t) represent the potential diagnostic interval of individual i, when
the first recorded feature of cancer observed during the year t is one of
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the NICE-2015-only features, and y0(i, t) indicates the potential diagnostic
interval of individual i, when his/her first recorded feature of cancer ob-
served during the year t is one of the NICE-2005 features. The ATT (t|W )
of the new guideline implementation conditional on W can be defined as
ATT (t|W ) = E[y1(i, t)− y0(i, t)|Wi, NICE2015,i = 1].
Following the same practice, from now on we drop the argument i. In order
to identify ATT (t|W ), we have to assume a variant version of the parallel
assumption. In particular, it is as follows:
Assumption A.2. E[y0(t) − y0(0)|W,NICE2015 = 1] = E[y0(t) −
y0(0)|W,NICE2015 = 0].
It is assumed that the average difference in the diagnostic intervals between
the new guideline implementation year and any year after the implementa-
tion for the control and treated groups, conditional on the other observed
factors W , would have been the same in the absence of the new guideline
implementation. Under Assumption A.2, by applying the event-study DID
method of Eq(A.3), the ATT (t|W ) can be identified and measured by λt
(t > 0) in Eq (A.3). It can be shown that
ATT (t|W ) = E[y1(t)− y0(t)|W,NICE2015 = 1]
= E[y1(t)− y0(0) + y0(0)− y0(t)|W,NICE2015 = 1]
= E[y1(t)− y0(0)|W,NICE2015 = 1]− E[y0(t)− y0(0)|W,NICE2015 = 1]
= E[y1(t)− y0(0)|W,NICE2015 = 1]− E[y0(t)− y0(0)|W,NICE2015 = 0]
=
[(
δ0 + δ1 + γt + λt +Wβ)−
(










Appendix B. Technical details for the semiparametric varying-
coefficient model
This appendix contains: (a) how to identify and measure the average treat-
ment effect on the treated at a particular time point by the semiparamet-
ric varying-coefficient model, and (b) how to estimate the semiparametric
varying-coefficient model using the kernel estimation method.
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Appendix B.1. The treatment effect identification and calculation
Consider the semiparametric varying-coefficient model specified in this paper:
y = δ0(ct) + δ1(ct)NICE2015 +Wβ(ct) + ε, (B.1)
As stated in the main text, ct represents the day relative to the new guideline
implementation, i.e. 23 June 2015. In particular, ct > 0 indicates a post-
official-implementation day, ct = 0 is the official implementation day, and
ct < 0 represents a pre-official-implementation day. Under a variant parallel
trend assumption, the estimated model coefficients can be used to identify
the average treatment effect of the revised guideline at ct (conditional on W
and related to a particular event) on the diagnostic interval of patients whose
first recorded feature of cancer was one of the NICE-2015-only features, i.e.
the average treatment effect for the treated group at time point ct. This is
indicated as ATT (ct|W ).
As mentioned in the paper, we can identify different types of treatment effect
of the revised guideline, including the treatment effects of official guideline
implementation and of the guideline’s content. To measure these effects, we
need to identify a specific date on which we believe they began. For the
official guideline implementation, we assume this to be 23 June 2015, i.e.
ct = 0 defined in our model. For guideline content, we illustrate the method
by selecting the date of a political announcement related to early signs of
cancer made on 30 June 2014, i.e. ct = −357, by the Secretary of State for
Health.
We can identify the treatment effect of the revised guidelines starting from
specific dates of interest, c0. For dates ct > c0, let y
1(i, ct) represent the
potential diagnostic interval of individual i, when his/her first recorded fea-
ture of cancer observed at time ct is one of the NICE-2015-only features,
and y0(i, ct) indicates the potential diagnostic interval of individual i, when
his/her first recorded feature of cancer observed at time ct is one of the NICE-
2005 features. The treatment effect of new guideline implementation on the
diagnostic interval for individual i at time ct (ct > c0) that is relevant to
the particular occurring at c0 can be naturally defined as y
1(i, ct)− y0(i, ct).
The identification problem for this treatment effect is that, for any particular
individual i, we do not observed both y1(i, ct) and y
0(i, ct). Owing to the
impossibility of computing the individual treatment effect, researchers often
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measure the average treatment effect for the treated, conditional on some ob-
served characteristics. In this study, we define the average treatment effect
of the guideline related to a particular event at ct (ct > c0) conditional on W
as ATTco(ct|W ) = E[y1(i, ct)− y0(i, ct)|Wi, NICE2015,i = 1].
To reduce notation, from now on we drop the individual argument i. In order
to identify ATTco(ct|W ), we need to assume:
Assumption B.1. E[y0(ct) − y0(co)|W,NICE2015 = 1] = E[y0(ct) −
y0(co)|W,NICE2015 = 0].
Assumption B.1 is a variant of the conventional parallel assumption and it
is crucial for identifying the treatment effect of guidelines related to a par-
ticular event using this semiparametric varying-coefficient model. It states
that, conditional on the regressors W , the average outcome (i.e. diagnostic
interval) for the treated group (NICE2015 = 1) would have followed a path
parallel to that of the control group (NICE2015 = 0) from the time that
the particular event of interest (ct = c0) occurred until time ct (ct > c0), in
the absence of the treatment (i.e. no event related to the guideline revision
happened).
Under Assumption B.1, by applying the semiparametric varying-coefficient
model, the conditional average treatment effect ATTco(ct|W ) can be ex-
pressed and calculated as:
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ATTco(ct|W ) = E[y1(ct)− y0(ct)|W,NICE2015 = 1]
= E[y1(ct)− y0(c0) + y0(c0)− y0(ct)|W,NICE2015 = 1]
= E[y1(ct)− y0(c0)|W,NICE2015 = 1]−
E[y0(ct)− y0(c0)|W,NICE2015 = 1]
= E[y1(ct)− y0(c0)|W,NICE2015 = 1]−
E[y0(ct)− y0(c0)|W,NICE2015 = 0]
=
[(
δ0(ct) + δ1(ct) +Wβ(ct))−
(









Appendix B.2. Kernel Estimation
In general, Eq.(B.1) can be written more compactly as
yi = X
′
iθ(Zi) + ui, i = 1, ... , n, (B.3)
where Xi is a column vector indicating all regressors of the ith individual,
with the first element of Xi is 1, i.e. the intercept term; Zi is the covariate (in
our model, Eq.(3), it is the time of the ith individual’s first observed cancer
feature relative to the revised guideline implementation in 2015); θ(Zi) is the
coefficient of regressors Xi, which is allowed to vary across Zi; yi and ui are
the ith individual’s diagnostic interval and error term, respectively; and n
is the sample size. In this study, we apply the kernel estimation method (Li
and Racine, 2010) to estimate Eq.(B.3). In particular, as Zi is continuous in










where ω (•) is a symmetric univariate density function; for example, we adopt
a univariate standard normal density function; and 0 < h <∞ is the smooth-
ing parameter for Z. Let S denote the whole set of possible values for Z.
For any z ∈ S, from Eq.(B.3) it can be shown that
θ(z) = [E(XiX
′
i |Zi = z )]
−1
[E(XiYi |Zi = z )] (B.5)
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When h is sufficiently large, then ω ((Zi − z)/h) → ω(0), which is constant
and unrelated to Z. Thus Z is completely smoothed out and θ̂(z) does not
depend on Z. In this sense, the magnitude of h indicates the relevance of
Z, such that, if Z is relevant, as n → ∞, the smoothing parameter h will
converge to 0 (Li and Racine, 2010).
We use a cross-validation method to choose the optimal smoothing parameter
























is the leave-one-out kernel estimator of θ(Zi).
Appendix B.3. Testing for coefficient functional specification
The pre-to-post and event-study DID models are special cases of the semi-
parametric varying-coefficient model. This enables a formal test of the para-
metric models by testing the parametric specification of θ(Z) using an ap-
proach proposed by Li and Racine (2010).
Specifically, let θ0(Z) denote the coefficient vector in Eq.(4) or Eq.(5), which
is a parametric function of Z. We test if θ(Z) is of a parametric function form
as defined by θ0(Z) over the whole set of possible values for Z. If it is not,
we should avoid using the parametric specification of Eq.(4) or Eq.(5), i.e. a
model specified by Eq.(1) or Eq.(2), due to its misspecification.
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To conduct this model specification test, we formulate the null hypothesis as
H0 : Pr (θ(Z) = θ0(Z)) = 1, i.e. the probability of varying-coefficient model’s
nonparametrically specified coefficient θ(Z) being equal to the parametrically
specified coefficient θ0(Z) of the pre-to-post or the event-study difference-in-









X ′iXjûiûjWĥ(Xi, Xj), (B.8)
where ĥ is the optimal smoothing parameter chosen by the cross-validation
method for the varying-coefficient model, and ûi is the estimated error from






d−→ N(0, 1) (B.9)








. A nonparametric boot-
strap procedure to approximate the null distribution of T̂n proposed by Li
and Racine (2010) is applied in this study.
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Appendix C. Robustness Check and Sensitivity Analysis
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Figure C.1: Mean diagnostic interval (95% confidence interval) by year, for NICE-2015-
only (red dashed line) and NICE-2005 (blue long-dashed line) patients, and for both groups
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95%CI Age coefficient (women)
(f) Age coefficient: F
Figure C.2: Semiparametric varying-coefficient analyses of diagnostic interval from 1 Jan
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95%CI England vs Wales or NI
(c) England vs Wales or NI
Figure C.3: Semiparametric varying-coefficient analyses of diagnostic interval from 1 Jan
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95% CI Most vs least deprived
(c) Most vs least deprived
Figure C.4: Semiparametric varying-coefficient analyses of diagnostic interval in England
from 1 Jan 2006 to 31 December 2017, adjusting for deprivation quintile (most deprived
quintiles 4 and 5 versus least deprived quintiles 1 to 3)
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Table C.1: Results of event-study difference-in-differences analysis (see Figure 2)a b
t (years relative
to 2015) Coefficient Value 95% CI P
δ0 3.88 3.727 to 4.042 <0.0001
δ1 0.007 –0.190 to 0.204 0.943
–10 γ−10 0.831 0.674 to 0.988 <0.0001
λ−10 0.300 0.031 to 0.568 0.029
–9 γ−9 –0.076 –0.215 to 0.062 0.277
λ−9 0.216 –0.029 to 0.462 0.084
–8 γ−8 –0.138 –0.267 to –0.009 0.035
λ−8 0.241 –0.004 to 0.486 0.053
–7 γ−7 –0.161 –0.288 to –0.035 0.013
λ−7 0 .273 0.039 to 0.507 0.022
–6 γ−6 –0.121 –0.255 to 0.012 0.074
λ−6 0.111 –0.137 to 0.359 0.379
–5 γ−5 –0.067 –0.198 to 0.064 0.317
λ−5 0.150 –0.094 to 0.394 0.227
–4 γ−4 –0.066 –0.190 to 0.058 0.297
λ−4 0.093 –0.142 to 0.327 0.437
–3 γ−3 –0.017 –0.146 to 0.112 0.795
λ−3 –0.001 –0.248 to 0.247 0.996
–2 γ−2 –0.125 –0.261 to 0.011 0.072
λ−2 0.079 –0.189 to 0.347 0.563
–1 γ−1 0.001 –0.134 to 0.136 0.987
λ−1 0.112 –0.140 to 0.365 0.383
+1 γ+1 0.091 –0.058 to 0.241 0.232
λ+1 –0.092 –0.393 to 0.207 0.545
+2 γ+2 –0.008 –0.157 to 0.140 0.911
λ+2 –0.306 –0.616 to 0.003 0.052
Age 0.001 –0.001 to 0.002 0.525
Sex (f vs m) 0.090 0.046 to 0.134 <0.0001
a Post-estimation link tests did not reveal any problems with the data specification of the difference-
in-differences model.
b No evidence of unobserved confounding was found using the omitted variable test (p=0.9744).
δ0 is mean log-transformed diagnostic interval for men aged 0 in the NICE-2005 group in 2015.
δ1 is the difference in mean log-transformed diagnostic interval between the NICE-2015-only and
NICE-2005 groups in 2015.
γt is the difference in mean log-transformed diagnostic interval in NICE-2005 groups between year
t and 2015.
λt is the difference in mean log-transformed diagnostic interval in year t compared with 2015 that
is attributable to NICE 2015.
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Table C.2: Robustness check for non-linear effect of age in the difference-in-differences regression
Estimand Including age-squared Including log(age)
Coeff. 95% CI p Coeff. 95% CI p
δ0 4.168 3.349 to 4.998 <0.0001 3.636 2.901 to 4.372 <0.0001
δ1 0.055 –0.050 to 0.160 0.305 0.056 –0.048 to 0.161 0.292
δ2 0.162 0.064 to 0.260 0.001 0.162 0.064 to 0.260 0.001
δ3 –0.071 –0.253 to 0.112 0.449 –0.071 –0.254 to 0.111 0.443
Age –0.010 –0.035 to 0.015 0.421 n/a n/a n/a
Age-squared 0.00009 –0.0001 to 0.0003 0.365 n/a n/a n/a
Log(age) n/a n/a n/a 0.058 –0.115 to 0.232 0.506
Sex (f vs m) 0.123 0.046 to 0.200 0.02 0.127 0.050 to 0.204 0.001
δ0 is mean log-transformed diagnostic interval for men aged 0 in the NICE-2005 group in the Pre cohort.
δ1 is the difference in mean log-transformed diagnostic interval in the Pre cohort between the NICE-2015-only and NICE-2005
groups.
δ2 is the Pre-to-Post change in mean log-transformed diagnostic interval attributable to NICE 2015 (see Eq. (A.1) .
Age at diagnosis was entered as a continuous variable.
Table C.3: Pre-to-post difference-in-differences regression analysis results by gender. Pre: 1 Aug
2012 to 31 Dec 2014 (n=1,205 men, n=1,038 women); Post: 1 Aug 2015 to 31 Dec 2017 (n=594
men, n=423 women)
Estimand Men (n=1,799) Women (n=1,461)
Coeff. 95% CI p Coeff. 95% CI p
δ0 3.687 3.380 to 3.995 <0.0001 3.992 3.659 to 4.326 <0.0001
δ1 0.093 –0.054 to 0.240 0.213 0.027 –0.119 to 0.173 0.719
δ2 0.071 –0.052 to 0.193 0.257 0.115 –0.035 to 0.265 0.132
δ3 –0.194 –0.447 to 0.059 0.133 –0.085 –0.345 to 0.176 0.523
Age 0.003 –0.002 to 0.007 0.240 0.0003 –0.005 to 0.004 0.881
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Table C.4: Results of event-study difference-in-differences analysis, by sex
tb Estimate Men Women
Coeff. 95% CI P Coeff. 95% CI P
δ0 3.784 3.584 to 3.985 <0.0001 4.071 3.834 to 4.309 <0.0001
δ1 0.034 -0.245 to 0.314 0.810 -0.024 -0.288 to 0.240 0.857
–10 γ−10 0.842 0.633 to 1.050 0.000 0.818 0.574 to 1.063 <0.0001
λ−10 0.321 –0.040 to 0.682 0.081 0.281 –0.097 to 0.659 0.145
–9 γ−9 –0.039 –0.204 to 0.126 0.642 –0.127 –0.333 to 0.079 0.225
λ−9 0.247 –0.079 to 0.574 0.137 0.202 –0.136 to 0.540 0.241
–8 γ−8 –0.136 –0.303 to 0.032 0.112 –0.144 –0.336 to 0.048 0.141
λ−8 0.200 –0.138 to 0.538 0.246 0.280 –0.051 to 0.611 0.097
–7 γ−7 –0.095 –0.251 to 0.061 0.233 –0.259 –0.464 to –0.054 0.013
λ−7 0.168 –0.184 to 0.520 0.349 0.403 0.072 to 0.735 0.017
–6 γ−6 –0.026 –0.188 to 0.137 0.756 –0.256 –0.469 to –0.043 0.019
λ−6 –0.066 –0.406 to 0.274 0.702 0.320 –0.024 to 0.664 0.068
–5 γ−5 –0.074 –0.238 to 0.090 0.378 –0.051 –0.255 to 0.153 0.623
λ−5 0.119 –0.215 to 0.453 0.484 0.173 –0.177 to 0.523 0.332
–4 γ−4 –0.071 –0.237 to 0.095 0.401 –0.056 –0.241 to 0.129 0.553
λ−4 0.227 –0.101 to 0.555 0.174 –0.037 –0.369 to 0.296 0.828
–3 γ−3 0.005 –0.163 to 0.174 0.951 –0.048 –0.249 to 0.153 0.636
λ−3 –0.040 –0.396 to 0.315 0.823 0.043 –0.309 to 0.396 0.809
–2 γ−2 –0.153 –0.321 to 0.016 0.075 –0.089 –0.292 to 0.114 0.388
λ−2 0.091 –0.268 to 0.450 0.618 0.057 –0.307 to 0.421 0.760
–1 γ−1 0.015 –0.162 to 0.192 0.867 –0.019 –0.226 to 0.187 0.853
λ−1 0.112 –0.234 to 0.459 0.524 0.121 –0.219 to 0.462 0.484
+1 γ+1 0.079 –0.118 to 0.276 0.432 0.114 –0.124 to 0.353 0.346
λ+1 –0.190 –0.560 to 0.181 0.315 0.036 –0.418 to 0.491 0.875
+2 γ+2 –0.027 –0.221 to 0.167 0.787 0.031 –0.205 to 0.267 0.796
λ+2 –0.337 –0.779 to 0.105 0.135 –0.299 –0.712 to 0.114 0.155
Age 0.002 –0.001 to 0.004 0.157 <0.0001 –0.003 to 0.002 0.716
Post-estimation link tests did not reveal any problems with the data specification of the difference-in-differences model.
Time, years relative to 2015.
δ0 is mean log-transformed diagnostic interval at age 0 in the NICE-2005 group in 2015.
δ1 is the difference in mean log-transformed diagnostic interval between the NICE-2015-only and NICE-2005 groups in 2015.
γt is the difference in mean log-transformed diagnostic interval in NICE-2005 groups between year t and 2015.
λt is the difference in mean log-transformed diagnostic interval in year t compared with 2015 that is attributable to NICE 2015.
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Table C.5: Pre-to-post difference-in-differences regression analysis results. Pre: 1 Aug
2012 to 31 Dec 2014 (n=2,243); Post: 1 Aug 2015 to 31 Dec 2017 (n=1,017). Including
interaction terms between Pre/Post and age and between Pre/Post and sex
Estimand Coeff. 95% CI p
δ0 3.8 3.5 to 4.1 <0.0001
δ1 0.06 0.04 to 0.2 0.258
δ2 0.06 0.4 to 0.5 0.810
δ3 0.1 0.3 to 0.04 0.125
δ4 0.08 0.02 to 0.2 0.128
δ5 0.09 0.07 to 0.3 0.265
δ6 0.001 –0.003 to 0.005 0.555




δ0 is mean log-transformed diagnostic interval for men at age 0 in
the NICE-2005 group in the Pre cohort.
δ1 is the difference in mean log-transformed diagnostic interval in the
Pre cohort between the NICE-2015-only and NICE-2005 groups, for
men aged 0.
δ2 is the Pre-to-Post difference in mean log-transformed diagnostic
interval in the NICE-2005 group, for men aged 0.
δ3 is the Pre-to-Post change in mean log-transformed diagnostic in-
terval attributable to NICE 2015.
δ4 is the female vs male difference in mean log-transformed diagnostic
interval in the NICE-2005 group at age 0.
δ5 is the Pre-to-Post difference in mean log-transformed diagnostic
interval attributable to being female.
δ6 is the mean change in log-transformed diagnostic interval for a
unit change in age in men in the Pre group.
δ7 is the Pre-to-Post difference in mean log-transformed diagnostic
interval attributable to a unit change in age.
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Table C.6: Event-study difference-in-differences analyses, including interaction terms be-
tween time and age, and time and sex
Estimand Coeff. 95% CI P
δ0 3.746 3.292 to 4.200 <0.0001
δ1 0.006 –0.194 to 0.205 0.956
γ−10 1.222 0.596 to 1.847 <0.0001
λ−10 0.294 0.024 to 0.564 0.033
ζ−10 –0.042 –0.287 to 0.204 0.740
η−10 –0.005 –0.014 to 0.003 0.237
γ−9 0.285 –0.358 to 0.928 0.384
λ−9 0.222 –0.027 to 0.470 0.080
ζ−9 –0.103 –0.328 to 0.122 0.369
η−9 –0.005 –0.013 to 0.004 0.325
γ−8 –0.292 –0.947 to 0.363 0.382
λ−8 0.242 –0.007 to 0.490 0.057
ζ−8 0.024 –0.204 to 0.252 0.835
η−8 0.002 –0.007 to 0.011 0.674
γ−7 0.205 –0.393 to 0.803 0.502
λ−7 0.282 0.043 to 0.521 0.021
ζ−7 –0.061 –0.287 to 0.165 0.598
η−7 –0.005 –0.013 to 0.004 0.267
γ−6 0.019 –0.596 to 0.633 0.952
λ−6 0.116 –0.136 to 0.368 0.365
ζ−6 –0.055 –0.277 to 0.167 0.628
η−6 –0.002 –0.010 to 0.007 0.703
γ−5 0.141 –0.481 to 0.762 0.656
λ−5 0.144 –0.102 to 0.391 0.251
ζ−5 0.049 –0.174 to 0.272 0.668
η−5 –0.003 –0.012 to 0.006 0.485
γ−4 0.151 –0.468 to 0.770 0.632
λ−4 0.103 –0.133 to 0.339 0.392
ζ−4 –0.098 –0.319 to 0.124 0.388
η−4 –0.003 –0.011 to 0.006 0.571
γ−3 0.098 –0.526 to 0.723 0.757
λ−3 0.001 –0.249 to 0.251 0.993
ζ−3 –0.017 –0.258 to 0.224 0.889
η−3 –0.002 –0.011 to 0.007 0.736
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γ−2 –0.151 –0.737 to 0.436 0.614
λ−2 0.077 –0.193 to 0.347 0.574
ζ−2 0.048 –0.174 to 0.270 0.672
η−2 0.000 –0.008 to 0.008 0.987
γ−1 0.001 –0.662 to 0.663 0.999
λ−1 0.118 –0.139 to 0.374 0.367
ζ−1 –0.032 –0.260 to 0.196 0.782
η−1 0.000 –0.009 to 0.009 0.968
γ+1 0.094 –0.715 to 0.902 0.820
λ+1 –0.096 –0.397 to 0.206 0.533
ζ+1 0.139 –0.129 to 0.407 0.308
η+1 –0.001 –0.012 to 0.011 0.900
γ+2 0.201 –0.535 to 0.937 0.592
λ+2 –0.316 –0.631 to –0.001 0.049
ζ+2 0.079 –0.213 to 0.371 0.597
η+2 –0.003 –0.014 to 0.007 0.537
υ1 0.002 –0.004 to 0.009 0.467
ψ1 0.109 –0.070 to 0.287 0.232
Notes for Appendix Table C.6:
δ0 is mean log-transformed diagnostic interval for men at age 0 in the NICE-
2005 group in 2015.
δ1 is the difference in mean log-transformed diagnostic interval between the
NICE-2015-only and NICE-2005 groups for men aged 0 in 2015.
γt is the difference in mean log-transformed diagnostic interval in NICE-2005
groups between year t and 2015.
λt is the difference in mean log-transformed diagnostic interval in year t com-
pared with 2015 that is attributable to NICE 2015.
φ1 the difference in mean log-transformed diagnostic interval between women
and men, at age 0 in NICE-2005 group in 2015.
ζt is the additional difference in mean log-transformed diagnostic interval in
year t compared with 2015 that is attributable to being female.
υ1 is the change in mean log-transformed diagnostic interval for a unit change
in age in men in NICE-2005 group in 2015.
ηt is the additional difference in mean log-transformed diagnostic interval in





















Table C.7: Robustness checks for pre-to-post difference-in-differences analyses: varying
the start time of the Pre and Post periods
Estimand Coeff. 95% CI P
Pre: 23/7/12–22/12/14 (n=2,257); Post: 23/7/15–22/12/17 (n=1,035)
δ0 3.797 3.577 to 4.017 <0.0001
δ1 0.062 –0.042 to 0.166 0.241
δ2 0.094 –0.036 to 0.191 0.059
δ3 –0.135 –0.322 to 0.051 0.155
Age 0.0009 -0.002 to 0.004 0.549
Sex (f vs m) 0.109 0.029 to 0.189 0.007
Pre: 13/7/12–12/12/14 (n=2,257); Post: 13/7/15–12/12/17 (n=1,055)
δ0 3.778 3.556 to 4.000 <0.0001
δ1 0.060 –0.045 to 0.164 0.263
δ2 0.092 –0.005 to 0.189 0.064
δ3 -0.119 -0.307 to 0.069 0.213
Age 0.001 -0.002 to 0.004 0.450
Sex (f vs m) 0.107 0.028 to 0.186 0.008
Pre: 3/7/12–2/12/14 (n=2,265); Post: 3/7/15–2/12/17 (n=1,062)
δ0 3.774 3.554 to 3.995 <0.0001
δ1 0.056 –0.048 to 0.161 0.287
δ2 0.081 –0.016 to 0.178 0.103
δ3 -0.118 -0.304 to 0.069 0.216
Age 0.001 -0.002 to 0.004 0.409
Sex (f vs m) 0.109 0.029 to 0.188 0.007
Pre: 23/6/12–22/11/14 (n=2,264); Post: 23/6/15–22/11/17 (n=1,073)
δ0 3.790 3.567 to 4.011 <0.0001
δ1 0.061 –0.043 to 0.164 0.249
δ2 0.097 0.001 to 0.192) 0.047
δ3 -0.114 -0.298 to 0.070 0.226
Age 0.001 -0.002 to 0.004 0.533
Sex (f vs m) 0.107 0.0280 to 0.186 0.008
δ0 is mean log-transformed diagnostic interval for men at age 0 in the NICE-2005 group in the Pre
cohort.
δ1 is the difference in mean log-transformed diagnostic interval in the Pre cohort between the NICE-
2015-only and NICE-2005 groups.
δ2 is the Pre to Post difference in mean log-transformed diagnostic interval in the NICE-2005 group.
δ3 is the Pre-to-Post change in mean log-transformed diagnostic interval attributable to NICE 2015.
Age was entered as a continuous variable.
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Table C.8: Robustness checks for pre-to-post difference-in-differences analyses: vary-
ing the start time and width of the Pre and Post periods
Estimand Coeff. 95% CI P
Pre: 1/7/13–31/7/13 (n=86); Post: 1/7/17–31/7/17 (n=22)
δ0 3.210 1.979 to 4.440 <0.0001
δ1 –0.157 –0.729 to 0.416 0.588
δ2 0.009 –0.464 to 0.483 0.968
δ3 –0.644 –1.477 to 0.188 0.128
Age 0.009 –0.008 to 0.026 0.302
Sex (f vs m) 0.177 –0.311 to 0.664 0.474
Pre: 1/1/13–31/12/13 (n=964); Post: 1/7/17–31/12/17 (n=294)
δ0 3.649 3.315 to 3.983 <0.0001
δ1 0.082 –0.076 to 0.240 0.306
δ2 0.125 –0.018 to 0.267 0.086
δ3 –0.393 –0.693 to -0.093 0.010
Age 0.002 –0.003 to 0.006 0.472
Sex (f vs m) 0.165 0.044 to 0.286 0.008
Pre: 16/3/14–31/12/14 (n=647); Post: 16/3/17–31/12/17 (n=221)
δ0 3.871 3.474 to 4.267 <0.0001
δ1 0.163 –0.026 to 0.353 0.091
δ2 –0.146 –0.295 to 0.024 0.054
δ3 –0.476 –0.807 to –0.146 0.005
Age 0.0004 –0.005 to 0.006 0.868
Sex (f vs m) 0.169 0.021 to 0.317 0.026
Pre: 1/1/06–22/6/15 (n=10,767); Post: 23/6/15–31/12/17 (n=1,075)
δ0 3.820 3.698 to 3.942 <0.0001
δ1 0.153 0.104 to 0.203 <0.0001
δ2 0.098 0.014 to 0.183 0.023
δ3 –0.215 –0.374 to –0.055 0.008
Age 0.0006 –0.001 to 0.002 0.501
Sex (f vs m) 0.091 0.046 to 0.136 <0.0001
δ0 is mean log-transformed diagnostic interval for men at age 0 in the NICE-2005 group in the Pre
cohort.
δ1 is the difference in mean log-transformed diagnostic interval in the Pre cohort between the NICE-
2015-only and NICE-2005 groups.
δ2 is the Pre to Post difference in mean log-transformed diagnostic interval in the NICE-2005 group.
δ3 is the Pre-to-Post change in mean log-transformed diagnostic interval attributable to NICE 2015.
Age was entered as a continuous variable. 52
Table C.9: Pre-to-post difference-in-differences regression
analyses, adjusted for region. Pre: 1 Aug 2012 to 31 Dec
2014; post: 1 Aug 2015 to 31 Dec 2017
Estimand Coeff. 95% CI p
δ0 3.976 3.746 to 4.205 <0.0001
δ1 0.061 –0.043 to 0.164 0.253
δ2 0.051 –0.047 to 0.149 0.305
δ3 –0.144 –0.328 to 0.040 0.126
Age 0.001 –0.002 to 0.004 0.581
Sex (f vs m) 0.110 0.030 to 0.190 0.007
Region –0.218 –0.306 to –0.129 <0.0001
δ0 is mean log-transformed diagnostic interval for men at age 0 in the
NICE-2005 group in the Pre cohort.
δ1 is the difference in mean log-transformed diagnostic interval in the
Pre cohort between the NICE-2015-only and NICE-2005 groups.
δ2 is the Pre to Post difference in mean log-transformed diagnostic in-
terval in the NICE-2005 group.
δ3 is the Pre-to-Post change in mean log-transformed diagnostic interval
attributable to NICE 2015.
Age was entered as a continuous variable; region as a binary variable
(England vs Wales or Northern Ireland.
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Table C.10: Event-study difference-in-differences analysis, adjusting for
region (England vs Wales or NI)
Time Estimand Coeff. 95% CI P
δ0 4.114 3.956 to 4.272 <0.0001
δ1 0.018 –0.179 to 0.215 0.857
–10 γ−10 0.868 0.712 to 1.023 <0.0001
λ−10 0.295 0.026 to 0.564 0.032
–9 γ−9 –0.027 –0.164 to 0.110 0.698
λ−9 0.193 –0.052 to 0.438 0.122
–8 γ−8 –0.093 –0.221 to 0.036 0.156
λ−8 0.221 –0.024 to 0.465 0.077
–7 γ−7 –0.120 –0.244 to 0.005 0.060
λ−7 0.256 0.020 to 0.491 0.034
–6 γ−6 –0.087 –0.220 to 0.046 0.199
λ−6 0.103 –0.144 to 0.349 0.414
–5 γ−5 –0.024 –0.154 to 0.106 0.718
λ−5 0.140 –0.103 to 0.383 0.260
–4 γ−4 –0.029 –0.151 to 0.093 0.638
λ−4 0.083 –0.150 to 0.316 0.485
–3 γ−3 0.010 –0.116 to 0.136 0.879
λ−3 0.000 –0.246 to 0.246 0.999
–2 γ−2 –0.086 –0.221 to 0.049 0.211
λ−2 0.064 –0.206 to 0.334 0.642
–1 γ−1 0.019 –0.115 to 0.152 0.783
λ−1 0.107 –0.146 to 0.359 0.407
+1 γ+1 0.078 –0.072 to 0.229 0.308
λ+1 –0.124 –0.427 to 0.180 0.425
+2 γ+2 –0.056 –0.201 to 0.089 0.450
λ+2 –0.318 –0.628 to –0.008 0.044
Age 0.000 –0.001 to 0.002 0.701
Sex (f vs m) 0.094 0.050 to 0.138 <0.0001
Region –0.309 –0.359 to –0.259 <0.0001
δ0 is mean log-transformed diagnostic interval for men aged 0 in the NICE-2005
group in 2015, in England.
δ1 is the difference in mean log-transformed diagnostic interval between the NICE-
2015-only and NICE-2005 groups in 2015, for men aged 0 in England.
γt is the difference in mean log-transformed diagnostic interval in NICE-2005 groups
between year t and 2015 in England for men aged 0.
λt is the difference in mean log-transformed diagnostic interval in year t compared
with 2015 that is attributable to NICE 2015.
Age at diagnosis was entered as a continuous variable; Region was entered as a
binary variable (England vs Wales or NI).
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Table C.11: Pre-to-post difference-in-differences regression analyses on England-only data,
adjusted for deprivation. Pre: 1 Aug 2012 to 31 Dec 2014; post: 1 Aug 2015 to 31 Dec
2017
Estimand Coeff. 95% CI p
δ0 3.6 3.3 to 3.9 <0.0001
δ1 0.08 –0.06 to 0.2 0.283
δ2 0.07 –0.08 to 0.2 0.376
δ3 –0.03 –0.3 to 0.2 0.810
Age 0.001 –0.003 to 0.005 0.491
Sex (f vs m) 0.08 –0.02 to 0.2 0.113
Deprivation 0.1 –0.03 to 0.2 0.147
δ0 is mean log-transformed diagnostic interval for men at age 0 in the
NICE-2005 group in the Pre cohort.
δ1 is the difference in mean log-transformed diagnostic interval in the
Pre cohort between the NICE-2015-only and NICE-2005 groups.
δ2 is the Pre to Post difference in mean log-transformed diagnostic
interval in the NICE-2005 group. δ3 is the Pre-to-Post change in mean
log-transformed diagnostic interval attributable to NICE 2015.
Age at diagnosis was entered as a continuous variable; deprivation as
a binary variable (most deprived quintiles 4 and 5 vs least deprived
quintiles 1-3).
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Table C.12: Event-study difference-in-differences analysis of England-
only data, adjusting for deprivation (most vs least)
Time Estimand Coeff. 95%CI P
δ0 3.691 3.484 to 3.899 <0.0001
δ1 –0.084 –0.373 to 0.205 0.568
–10 γ−10 0.959 0.738 to 1.181 <0.0001
λ−10 0.428 0.045 to 0.810 0.028
–9 γ−9 0.005 –0.165 to 0.175 0.955
λ−9 0.317 –0.023 to 0.658 0.068
–8 γ−8 –0.068 –0.234 to 0.099 0.425
λ−8 0.305 –0.039 to 0.650 0.082
–7 γ−7 –0.107 –0.269 to 0.056 0.198
λ−7 0.399 0.068 to 0.731 0.018
–6 γ−6 –0.052 –0.232 to 0.129 0.574
λ−6 0.198 –0.164 to 0.560 0.283
–5 γ−5 –0.008 –0.179 to 0.163 0.926
λ−5 0.227 –0.102 to 0.556 0.176
–4 γ−4 –0.058 –0.219 to 0.104 0.483
λ−4 0.198 –0.137 to 0.534 0.245
–3 γ−3 0.013 –0.150 to 0.177 0.873
λ−3 0.076 –0.272 to 0.424 0.668
–2 γ−2 –0.116 –0.297 to 0.064 0.207
λ−2 0.204 –0.185 to 0.593 0.304
–1 γ−1 0.114 –0.064 to 0.292 0.209
λ−1 0.189 –0.168 to 0.545 0.298
+1 γ+1 0.195 –0.010 to 0.400 0.062
λ+1 0.102 –0.325 to 0.530 0.638
+2 γ+2 0.075 –0.135 to 0.286 0.483
λ+2 –0.226 –0.720 to 0.268 0.370
Age 0.001 –0.001 to 0.003 0.437
Sex (f vs m) 0.085 0.028 to 0.142 0.003
Deprivation 0.069 0.002 to 0.136 0.043
δ0 is mean log-transformed diagnostic interval for men aged 0 in the NICE-2005
group in 2015, in the least deprived quintiles (4 & 5).
δ1 is the difference in mean log-transformed diagnostic interval between the NICE-
2015-only and NICE-2005 groups in 2015, for men aged 0 in quintiles 4 & 5.
γt is the difference in mean log-transformed diagnostic interval in NICE-2005
groups between year t and 2015 for men aged 0 in quintiles 4 & 5.
λt is the difference in mean log-transformed diagnostic interval in year t compared
with 2015 that is attributable to NICE 2015.
Age at diagnosis was entered as a continuous variable.
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